Literature DB >> 32627854

Prognostic significance of histologic grade and Ki-67 proliferation index in follicular lymphoma.

Tian Xue1,2, Bao-Hua Yu1,2, Wan-Hui Yan1,2, Xiang-Nan Jiang1,2, Tian Tian1,2, Xiao-Yan Zhou1,2, Xiao-Qiu Li1,2.   

Abstract

The prognostic value of histologic grading and the Ki-67 proliferation index in follicular lymphoma (FL) is controversial. This study investigated the clinical usefulness of these two factors in Asian FL patients. Four hundred and thirty-three patients diagnosed with FL were retrospectively reviewed with a median follow-up time of 47.0 months (range, 24.0-168.0). The 10-year overall survival (OS) rate and progression-free survival (PFS) rate were 91.0% and 47.1%, respectively. Grade 3B and grade 3B with diffuse large B cell lymphoma (DLBCL) showed a better PFS than grade 1-3A (P < 0.001), and similar findings were noted in patients who received rituximab-containing regimens (P = 0.002). In contrast, no significant differences in terms of OS or PFS were observed between grades 1-2 and 3A. In addition, patients with Ki-67 ≥ 30% had a significantly better PFS than patients with Ki-67 < 30% (P = 0.014), although the difference was eliminated in the multivariate analysis. Both grade and Ki-67 index had no impact on prognosis in patients who did not receive rituximab treatment. In conclusion, grade 3A is closely related to grade 1-2, as reflected by a similar indolent clinical course and a lower PFS rate than grade 3B/3B + DLBCL. In addition, a higher Ki-67 index seems to have a positive effect on PFS in FL patients.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  Ki-67; follicular lymphoma; grade; progression-free survival; rituximab

Year:  2020        PMID: 32627854     DOI: 10.1002/hon.2778

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  4 in total

1.  Survival Analysis of Hepatosplenic T Cell Lymphoma: A Population-Based Study Using SEER.

Authors:  Yajun Li; Kailin Chen; Chaohui Zuo; Ruolan Zeng; Yizi He; Xiaoyan Chen; Ling Xiao; Hui Zhou
Journal:  Int J Gen Med       Date:  2021-11-17

2.  Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis.

Authors:  Tevfik Hatipoğlu; Esra Esmeray Sönmez; Xiaozhou Hu; Hongling Yuan; Ayça Erşen Danyeli; Ahmet Şeyhanlı; Tuğba Önal-Süzek; Weiwei Zhang; Burcu Akman; Aybüke Olgun; Sermin Özkal; İnci Alacacıoğlu; Mehmet Ali Özcan; Hua You; Can Küçük
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

3.  Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET/CT.

Authors:  Hongyan Li; Min Wang; Yajing Zhang; Fan Hu; Kun Wang; Chenyang Wang; Zairong Gao
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

4.  Immune infiltrate diversity confers a good prognosis in follicular lymphoma.

Authors:  Richard Byers; Kim Linton; Anna-Maria Tsakiroglou; Susan Astley; Manàs Dave; Martin Fergie; Elaine Harkness; Adeline Rosenberg; Matthew Sperrin; Catharine West
Journal:  Cancer Immunol Immunother       Date:  2021-04-30       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.